NRX Pharmaceuticals Overview
NRX Pharmaceuticals (NRXP) has a ROE of 13811.76%, above the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow13811.76%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, NRXP shows a ROE of 13811.76%. That is above the Healthcare sector average of 22.01%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 22.01%. NRX Pharmaceuticals is at 13811.76%, which is higher that average. That is roughly 62653.1% above the sector mean. Use the comparison chart on this page to see how NRXP stacks up against individual peers as well.
Check the historical chart to see whether NRXP's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare NRX Pharmaceuticals with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has NRX Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 13811.76%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 22.01%, while NRXP is at 13811.76%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
